ClinicalTrials.gg
CompletedNCT02471196NebulaUpdated Feb 15, 2018

Efficacy of ORM-12741 on Agitation/Aggression Symptoms in Alzheimer's Disease

A Phase 2 interventional study of ORM-12741 and ORM-12741 in Alzheimer's Disease, sponsored by Orion Corporation, Orion Pharma. Completed at 1 site in Finland. Open to participants aged 55 Years to 90 Years. Per ClinicalTrials.gov, last updated 2018-02-15.

Sponsored by Orion Corporation, Orion Pharma · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
308
Allocation
Randomized
Ages
55 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 68 studies in Alzheimer Disease with a site in Finland — 4 open to participants now, 7 under way, 1 of them phase 3. Alzheimer Disease · Finland.

Enrollment
35th of 61
308 · median 390
Started
2015
with 5 others
Phase 2
15 of 68
1 open now
Registered
33rd of 68
by date

Among the 68 studies in Alzheimer Disease with a site in Finland, this one is the 35th largest by enrollment of the 61 interventional ones that give a count, is one of 6 that started in 2015, is one of 15 in phase 2, and was the 33rd registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

4 of the 68 studies in Alzheimer Disease with a site in Finland are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Finland have not opened yet or have stopped. Only those recruiting at a site in Finland →

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 55 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 68 studies in Alzheimer Disease with a site in Finland, or all of them as a file.
02

Study summary

This study evaluates the effect of ORM-12741 on agitation/aggression symptoms in Alzheimer's disease. Two thirds of the patients will receive ORM-12741 and one third will receive placebo.

Read the detailed description

ORM-12741 is a potent and selective alpha-2C adrenoceptor (AR)-antagonist. Previous results suggest that the compound may have positive effects on both cognitive and neuropsychiatric symptoms of Alzheimer's Disease. In this study, the effect of ORM-12741 will be evaluated on agitation/aggression symptoms and other neuropsychiatric symptoms. Furthermore, cognition and psychotic and depressive symptoms will be evaluated.

03

Conditions studied

  • Alzheimer's Disease

Browse trials for

04

Who can participate

Ages eligible
55 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written (IC) for participation in the study (co-signed by the subject's next of kin or caregiver, or other legally acceptable representative.
  • Written IC obtained from a consistently available caregiver informant who is knowledgeable of the subject's condition and its progression and is willing to accompany the subject to all visits and supervise the administration of the study medication.
  • Age of 55-90 years (inclusive).
  • Male or female subjects with diagnosis of probable Alzheimer's Disease.
  • Brain imaging (computed tomography [CT] or magnetic resonance imaging [MRI]) consistent with a diagnosis of Alzheimer's Disease (within 18 months or at screening).
  • (MMSE) score between 10-24 (inclusive).
  • agitation meeting the International Psychogeriatric Association Provisional Criteria for Agitation in Cognitive Impairment. The agitation symptoms need to have been present for at least 4 weeks before the screening visit.
  • Neuropsychiatric Inventory agitation/aggression item score at least 4 at screening visit.

Exclusion criteria

Exclusion Criteria:

  • Modified Hachinski Ischemia Score (MHIS) > 4.
  • Changes in AChE inhibitor (donepezil, rivastigmine or galantamine) dosing within 2 months prior to screening.
  • Changes in memantine dosing within 2 months prior to the screening.
  • Changes in antidepressant dosing or addition of another antidepressant medication within 2 months prior to the screening.
  • Use of antipsychotics at any dose within 1 month prior to screening.
  • Use of benzodiazepines, other than short-acting sleep medications, for night at a maximum of 3 nights/week, within 2 months prior to screening.
  • Use of any anticholinergic medication within 2 months prior to screening.
  • Current use (within the 30 days prior to screening) of medications with known relevant alpha-2C AR affinity (e.g. mirtazapine, mianserin, clonidine, guanfacine or tizanidine) or with high noradrenaline transporter affinity (reboxetine, venlafaxine or duloxetine).
  • Current use of other psychotropic agents, unless the dosing has been stable during the last 2 months prior to the screening.
  • Myocardial infarction or other ischemic cardiac disease, heart failure, or arrhythmia tendency within the past 2 years.
  • Current or history of within 5 years before screening.
  • Suicidal ideation in the 6 months before screening or current suicide risk based on the Colombia-Suicide Severity Rating Scale (C-SSRS) (items 4 and 5 exclusionary) or current risk of suicide based on the investigator's judgement.
  • Specific findings in MRI or CT that could in the opinion of the investigator affect cognitive function (such as cortical infarct or silent lacuna in a region known to affect cognition).
  • Supine heart rate \< 48 bpm or > 100 bpm.
  • Systolic blood pressure (SBP) > 160 mmHg or diastolic blood pressure (DBP) > 100 mmHg after a 5-minute rest.
  • Symptomatic orthostatic hypotension.
  • -Fridericia (QTcF) repeatedly > 450 ms in males or > 470 ms in females.
  • Clinically significantly abnormal thyroid-stimulating hormone (TSH), vitamin B12 or folate serum levels at screening.
  • Resides in a skilled nursing facility.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
308 participants (actual)

Study arms

  • Experimental
    ORM-12741 low dose

    ORM-12741 low dose twice a day for 12 weeks.

    Drug: ORM-12741

  • Experimental
    ORM-12741 high dose

    ORM-12741 high dose twice a day for 12 weeks.

    Drug: ORM-12741

  • Placebo comparator
    Placebo

    Placebo twice a day for 12 weeks.

    Drug: Placebo

Interventions

  • ORM-12741 low dose twice a day

  • ORM-12741 high dose twice a day

  • DrugPlacebo

    Placebo twice a day

06

What researchers measure

Primary outcomes

  1. Efficacy on aggression/agitation symptoms measured by Neuropsychiatric Inventory Clinician Rating scale

    Time frame: 12 weeks

Secondary outcomes

  1. Efficacy on aggression/agitation symptoms and overall clinical status measured by Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change

    Time frame: 12 weeks

  2. Efficacy on cognitive symptoms measured by Cognitive Drug Research computerized test battery

    Time frame: 12 weeks

  3. Efficacy on daily living measured by Alzheimer's Disease Co-operative Study - Activities of Daily Living inventory

    Time frame: 12 weeks

  4. Safety measured by assessing adverse events

    Time frame: 12 weeks

  5. Plasma concentrations of ORM ORM-12741, metabolites and possible other Alzheimer's disease medication

    Time frame: 12 weeks

  6. Efficacy on aggression/agitation symptoms measured by Cohen Mansfield Agitation Inventory

    Time frame: 12 weeks

  7. Efficacy on cognitive symptoms measured by Alzheimer's Disease Assessment Scale

    Time frame: 12 weeks

  8. Safety measured by vital signs

    Time frame: 12 weeks

  9. Safety measured by electrocardiogram

    Time frame: 12 weeks

  10. Safety measured by laboratory variables

    Time frame: 12 weeks

07

Study locations

1 site
  • Clinical Research Services Turku - CRST Oy
    Turku, Finland
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2015 to primary completion in Oct 2017, 25 months.

Of 131 industry-sponsored phase 2 interventional studies under Alzheimer Disease, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 39. This study's 25 months is close to that.

Counting every sponsor, half of 259 studies reached it within 37 months; a quarter within 21 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2015
First posted
Jun 15, 2015
StartActual
Aug 14, 2015
Primary completionActual
Oct 9, 2017
CompletionActual
Dec 4, 2017
Last update
Feb 15, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 15, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02471196
Responsible party
Sponsor
First posted
Jun 15, 2015
Start date
Aug 14, 2015
Primary completion
Oct 9, 2017
Completion
Dec 4, 2017
Last update
Feb 15, 2018

Study contacts

Juha Rinne, Prof
principal investigator · Clinical Research Services Turku - CRST Oy

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ORM-12741

Start the discussion